利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.038 秒)

    Humanized antibodies
    8.
    发明授权
    Humanized antibodies 失效
    人源化抗体

    公开(公告)号：US06872392B2

    公开(公告)日：2005-03-29

    申请号：US10195752

    申请日：2002-07-16

    申请人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    发明人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K16/18 ,  C07K16/46 ,  C12P21/04 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  C07K16/00

    CPC分类号： C07K16/3084 ,  A61K38/00 ,  C07K16/18 ,  C07K16/464 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  Y10S530/867

    摘要： Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured to produce a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but show a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

    摘要翻译： 通过将分离自产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤的杂交瘤分离的重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入含有人类的表达载体来构建嵌合人抗体表达载体 抗体重链恒定区或人抗体轻链恒定区编码cDNA。 将表达载体导入动物细胞中，培养由此获得的转化体以产生与神经节苷脂GM2反应的嵌合人抗体。 与小鼠单克隆抗体相反，本发明的嵌合人抗体不会引起患者体内的抗小鼠免疫球蛋白抗体的产生，但是显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期 例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

    Humanized antibodies
    9.
    发明授权
    Humanized antibodies 失效
    人源化抗体

    公开(公告)号：US06423511B1

    公开(公告)日：2002-07-23

    申请号：US09393385

    申请日：1999-09-10

    申请人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    发明人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    IPC分类号： C12P2104

    CPC分类号： C07K16/3084 ,  A61K38/00 ,  C07K16/18 ,  C07K16/464 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  Y10S530/867

    摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

    摘要翻译： 通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体， 含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。 将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。 与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期 例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

    DNA encoding humanized antibodies specific for the ganglioside GM.sub.2
    10.
    发明授权
    DNA encoding humanized antibodies specific for the ganglioside GM.sub.2 失效
    编码针对神经节苷脂GM2的人源化抗体的DNA

    公开(公告)号：US5874255A

    公开(公告)日：1999-02-23

    申请号：US438562

    申请日：1995-05-10

    申请人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    发明人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

    IPC分类号： A61K38/00 ,  C07K16/18 ,  C07K16/46 ,  C12N1/21 ,  C12N15/13 ,  C12P21/08 ,  C12P21/04 ,  C07H21/04 ,  C12N15/00

    CPC分类号： C07K16/3084 ,  C07K16/18 ,  C07K16/464 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  C07K2319/035 ,  Y10S530/867

    摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

    摘要翻译： 通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体， 含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。 将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。 与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期 例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。